Portal:COVID-19/FeaturedPathways
From WikiPathways
Line 1: | Line 1: | ||
== SARS-CoV-2 Pathways == | == SARS-CoV-2 Pathways == | ||
- | {| style="margin: 10px; background-color:# | + | {| style="margin: 10px; background-color:#407F7F" |
|width=100px; cell padding=50px|{{#pwImage:Pathway:WP4846|250px||SARS-CoV-2 and COVID-19 Pathway}} | |width=100px; cell padding=50px|{{#pwImage:Pathway:WP4846|250px||SARS-CoV-2 and COVID-19 Pathway}} | ||
Collaborative project for curation of biological processes involved in the COVID-19 disease after SARS-Cov-2 infection. | Collaborative project for curation of biological processes involved in the COVID-19 disease after SARS-Cov-2 infection. | ||
Line 11: | Line 11: | ||
|- | |- | ||
|} | |} | ||
- | {| style="margin: 10px; background-color:# | + | {| style="margin: 10px; background-color:#407F7F" |
|width=100px|{{#pwImage:Pathway:WP4876|250px||Activation of NLRP3 Inflammasome by SARS-CoV-2}} | |width=100px|{{#pwImage:Pathway:WP4876|250px||Activation of NLRP3 Inflammasome by SARS-CoV-2}} | ||
Orf3a from SARS-CoV has been shown to bind TRAF3 and activate the NLRP3 inflammasome. | Orf3a from SARS-CoV has been shown to bind TRAF3 and activate the NLRP3 inflammasome. | ||
Line 21: | Line 21: | ||
|- | |- | ||
|} | |} | ||
- | {| style="margin: 10px; background-color:# | + | {| style="margin: 10px; background-color:#407F7F" |
|width=100px|{{#pwImage:Pathway:WP4904|250px||LDLRAD4 pathway in COVID-19}} | |width=100px|{{#pwImage:Pathway:WP4904|250px||LDLRAD4 pathway in COVID-19}} | ||
|width=100px|{{#pwImage:Pathway:WP4936|250px||Overview of perturbations to host-cell autophagy, induced by distinct proteins of SARS-CoV-2 (Homo sapiens)}} | |width=100px|{{#pwImage:Pathway:WP4936|250px||Overview of perturbations to host-cell autophagy, induced by distinct proteins of SARS-CoV-2 (Homo sapiens)}} | ||
Line 29: | Line 29: | ||
== Other coronaviruses: MERS, SARS-CoV, etc == | == Other coronaviruses: MERS, SARS-CoV, etc == | ||
- | {| style="margin: 10px; background-color:# | + | {| style="margin: 10px; background-color:#407F7F" |
|width=100px|{{#pwImage:Pathway:WP4853|250px||Coronavirus lipid metabolism}} | |width=100px|{{#pwImage:Pathway:WP4853|250px||Coronavirus lipid metabolism}} | ||
Lipid metabolism alternations that are related to infection by the corona virus. | Lipid metabolism alternations that are related to infection by the corona virus. | ||
Line 37: | Line 37: | ||
|- | |- | ||
|} | |} | ||
- | {| style="margin: 10px; background-color:# | + | {| style="margin: 10px; background-color:#407F7F" |
|width=100px|{{#pwImage:Pathway:WP4861|250px||ER stress response in Coronavirus infection}} | |width=100px|{{#pwImage:Pathway:WP4861|250px||ER stress response in Coronavirus infection}} | ||
|width=100px|{{#pwImage:Pathway:WP4799|250px||Downregulation of ACE2 expression by SARS-CoV infection and SARS-CoV Spike protein}} | |width=100px|{{#pwImage:Pathway:WP4799|250px||Downregulation of ACE2 expression by SARS-CoV infection and SARS-CoV Spike protein}} | ||
Line 47: | Line 47: | ||
== More about ACE2 == | == More about ACE2 == | ||
- | {| style="margin: 10px; background-color:# | + | {| style="margin: 10px; background-color:#407F7F" |
|width=100px|{{#pwImage:Pathway:WP554|250px||ACE Inhibitor Pathway}} | |width=100px|{{#pwImage:Pathway:WP554|250px||ACE Inhibitor Pathway}} | ||
|width=100px|{{#pwImage:Pathway:WP2729|250px||Metabolism of Angiotensinogen to Angiotensins (Reactome)}} | |width=100px|{{#pwImage:Pathway:WP2729|250px||Metabolism of Angiotensinogen to Angiotensins (Reactome)}} |
Revision as of 06:56, 11 September 2020
SARS-CoV-2 Pathways
Image does not exist Collaborative project for curation of biological processes involved in the COVID-19 disease after SARS-Cov-2 infection. |
Image does not exist SARS-CoV-2 includes a novel Orf10 that interacts with multiple members of the Cullin 2 ubiquitin ligase complex. |
Image does not exist The induction and signaling of type I interferon with specific SARS-CoV-2 protein and relevant drug. |
Image does not exist |
Image does not exist Orf3a from SARS-CoV has been shown to bind TRAF3 and activate the NLRP3 inflammasome. |
Image does not exist |
Image does not exist Experimental pathway to investigate overlap of virus-host interaction and adverse outcome pathways |
Image does not exist Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis |
Image does not exist |
Image does not exist |
Other coronaviruses: MERS, SARS-CoV, etc
Image does not exist Lipid metabolism alternations that are related to infection by the corona virus. |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
More about ACE2
Image does not exist |
Image does not exist |
List of featured pathways:
- Pathway:WP4846
- Pathway:WP4860
- Pathway:WP4868
- Pathway:WP4927
- Pathway:WP4876
- Pathway:WP4883
- Pathway:WP4891
- Pathway:WP4884
- Pathway:WP4904
- Pathway:WP4936